Capricor/$CAPR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Capricor
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
- Ticker
- $CAPR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 231
- Headquarters
- San Diego, United States
- Website
- www.capricor.com
Capricor Metrics
BasicAdvanced
$371M
-
-$2.47
0.53
-
Price and volume
Market cap
$371M
Beta
0.53
52-week high
$40.37
52-week low
$2.96
Average daily volume
3.3M
Financial strength
Current ratio
7.346
Quick ratio
7.219
Long term debt to equity
0.364
Total debt to equity
0.37
Interest coverage (TTM)
-44.38%
Profitability
EBITDA (TTM)
-133.066
Effective tax rate (TTM)
-0.00%
Management effectiveness
Return on assets (TTM)
-33.63%
Return on equity (TTM)
-73.70%
Valuation
Price to book
1.32
Price to tangible book (TTM)
1.51
Price to free cash flow (TTM)
-2.58
Free cash flow yield (TTM)
-38.76%
Free cash flow per share (TTM)
-2.473
Growth
Earnings per share change (TTM)
48.91%
3-year earnings per share growth (CAGR)
28.33%
10-year earnings per share growth (CAGR)
-12.22%
What the Analysts think about Capricor
Analyst ratings (Buy, Hold, Sell) for Capricor stock.
Analyst projections of the future price of Capricor stock.
Bulls say / Bears say
In the 106-person, placebo-controlled HOPE-3 trial, deramiocel met its upper-limb primary endpoint, with a 4.55 percentage-point advantage on PUL 2.0 (p=0.029). The peer-reviewed result provides clinical evidence for the company’s lead treatment. (The Lancet)
In the HOPE-3 extension, patients who switched from placebo to deramiocel had a 76% slower rate of upper-limb decline in their first treatment year, while those treated throughout had similar decline rates across both years. This offers a positive durability signal, though the extension analysis was not powered for formal comparisons. (Capricor Therapeutics)
The FDA accepted Capricor’s major amendment with additional HOPE-3 data and is reviewing a proposed indication focused on upper-limb function; the target decision date is 22 November. This preserves a near-term regulatory route after the company refocused its application. (Capricor Therapeutics)
FDA reviewers questioned changes to the trial’s statistical analyses, and an advisory panel voted 9–3 that the evidence did not establish effectiveness for DMD-related cardiomyopathy. The vote was not on the company’s refined upper-limb claim, but it highlights material regulatory risk. (Reuters, Reuters)
The 24-month extension was open-label and not powered for month-24 comparisons; its comparison with natural-history predictions was descriptive and not statistically tested. That limits how much these additional results can settle questions about efficacy. (Capricor Therapeutics)
Capricor says the US distribution agreement’s pricing structure could impede patient access and is seeking to rescind it; the dispute is expected to move to arbitration. Unresolved partner terms could complicate launch economics and access even if deramiocel is approved. (Capricor Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 19 Oct 2026.
Capricor Financial Performance
Revenues and expenses
Capricor Earnings Performance
Company profitability
Upcoming events
No upcoming events
Capricor News
AllArticlesVideos
Capricor Highlights Two-Year Deramiocel Data as FDA Decision Nears
MarketBeat4 weeks ago
CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
Business Wire1 month ago
CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action
Newsfile Corp1 month ago
Funds containing Capricor
Fund name | Fund size | $CAPR weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
Xtrackers MSCI World Small Cap$XSWC | $183M | 0.00% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.00% |
SPDR MSCI All Country World IM€SPYI | $7.7B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.